Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 4008-4016

  Stearns, Vered ^a   Jacobs, Lisa K ^a   Fackler, Mary Jo ^a   Tsangaris, Theodore N ^a,g   Rudek, Michelle A ^a   Higgins, Michaela ^a,f   Lange, Julie ^a   Cheng, Zandra ^c,i   Slater, Shannon A ^a   Jeter, Stacie C ^a   Powers, Penny ^a   Briest, Susanne ^a,h   Chao, Calvin ^e   Yoshizawa, Carl ^e   Sugar, Elizabeth ^a,b   Espinoza Delgado, Igor ^d   Sukumar, Saraswati ^a   Gabrielson, Edward ^a   Davidson, Nancy E ^a,j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c ANNE ARUNDEL MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Genomic Health Inc   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ GRIFFIN HOSPITAL   (United States)

^j UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; CASPASE 3; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; VORINOSTAT;

ADULT; AGED; ANOREXIA; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPIGENETICS; FATIGUE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION TEST; MASTECTOMY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARTIAL MASTECTOMY; POSTOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TASTE DISORDER; THROMBOCYTE COUNT; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AURORA KINASE A; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE PROTEINS; COMBINED MODALITY THERAPY; CYCLIN B1; FEMALE; HUMANS; HYDROXAMIC ACIDS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; PROSPECTIVE STUDIES; TRANS-ACTIVATORS; TRANSCRIPTOME;

EID: 84881143035     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0033     Document Type: Article

References (23)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
2. Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest 2007;25:659-65.
3. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-88.
4. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
5. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, et al. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 2002;22:1497-504.
6. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000;6:849-66.
7. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-7.
8. Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010;10: 1029-39.
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
10. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
11. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-52.
12. Swift-Scanlan T, Blackford A, Argani P, Sukumar S, Fackler MJ. Twocolor quantitative multiplex methylation-specific PCR. Biotechniques 2006;40:210-9.
13. Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2006;840: 108-15.
14. Ratain MJ. Bar the windows but open the door to randomization. J Clin Oncol 2010;28:3104-6.
15. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005;11(24 Pt 1): 8623-31.
16. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 2006;66:6370-8.
17. Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 2012;17:191-204.
18. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
19. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 2003;3: 187-99.
20. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)- alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001; 61:7025-9.
21. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008;14:7138-42.
22. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104: 1828-35.
23. Connolly RM, Jankowitz RC, Andreopoulou E, Allred JB, Jeter SC, Zorzi J, et al. A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) and entinostat (MS-275) in patients with advanced breast cancer. Cancer Res 2011;7:Supplement 3, OT-01-6: A.